Combination therapy involving tiragolumab and atezolizumab (PD-L1 inhibitor) is currently being evaluated as a frontline treatment for PD-L1-positive R/M HNSCC in the SKYSCRAPER-09 trial (NCT04665843). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.